AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod
Shares of Amneal Pharmaceuticals (AMRX) extended their gains after the closing bell on Friday after the company said the U.S. Food and Drug Administration (FDA) had approved its lanreotide injection and that the product would go on sale immediately.The stock closed at $18.71, up 2.35% in regular tr…